Aman U. Buzdar, MD
Professor of Medicine
Department of Breast Medical Oncology
University of Texas MD Anderson Cancer Center
Joseph R. Singer, MD
Integrated Research Network
CME and CPE, 1 hour
This is the first program in a two-part series based on live audioconference presentations.
Breast cancer is the second leading cause of death from cancer in women (after lung cancer). It is the number one killer of women under the age of 54. The American Cancer Society estimates that in 2005, more than 200,000 women in the United States will have been newly diagnosed with breast cancer and more than 40,000 will die of it in that year, alone. According to Surveillance Epidemiology and End Results data, the average number of years of life lost for every woman who dies of breast cancer is 19. This represents more than 780,000 person-years of life lost in the United States, costing the nation more than $6 billion per year in medical costs and lost productivity. It is now estimated that approximately one out of every eight women will develop breast cancer in her lifetime. Preventing disease recurrence is perhaps the singular most effective way of reducing resource utilization. Since approximately two-thirds of breast cancer patients have estrogen-dependent tumors, it makes sense to examine clinical trial evidence regarding agents that block estrogen production and prevent disease recurrence. For more than 30 years tamoxifen has been the gold standard chemotherapeutic treatment for hormone-receptor-positive breast cancers. Today, third-generation aromatase inhibitors are increasingly being advocated as the preferable and more effective treatment for post-menopausal breast cancer patients in the adjuvant setting. These and other treatments, including trastuzumab, are helping to keep patients alive for periods longer than could have been imagined a decade ago.
. Target Audience
Managed Care Medical Directors, Pharmacy Directors, and other physicians and pharmacists interested in the management of breast cancer.
Upon completion of this educational activity, the participant should be able to:
Explain the mechanism of action of aromatase and estrogen in the pathophysiology of breast cancer.
Outline strategies for cost effective approaches to managing breast cancer.
Review the major clinical trials that evaluate the function and therapeutic value of pharmacologic agents that block estrogen production.
Describe the biology and epidemiology of breast cancer and its impact on resource utilization.
It is the policy of AKH Inc. to ensure independence, objectivity, scientific rigor, and integrity in all of its continuing education activities. The faculty must disclose to participants any significant relationships with commercial interests whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflict of interest is resolved by AKH prior to accreditation of the activity.
Dr. Buzdar discloses that he has received research fees, honoraria, and travel reimbursement from AstraZeneca.
Dr. Singer discloses that his employer, HealthCore Inc., is a health outcomes and medical research company that provides services to many pharmaceutical and biotech companies.
This educational activity may contain discussion of published and/or investigational uses of agents for the treatment of breast cancer. Some uses of these agents may not have been approved by the FDA. Plase refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Credit Statements
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of AKH Inc. and Medical Communications Media, Incorporated. AKH Inc. is accredited by the ACCME to provide continuing medical education for physicians.
AKH Inc. designates this educational activity for a maximum of 1.0 AMA PRA Category 1 . Physicians should only claim credit commensurate with the extent of their participation in the activity. Credit TM
AKH Inc. is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.
This program has been assigned the Universal Program Number 077-999-06-003-H01 and is acceptable for 1.0 contact hour (0.1 CEUs) in states that recognize ACPE-approved providers.
Participants must successfully complete the post-test (70% or higher) and submit an evaluation to receive credit.
Commercial Support Statements
This program is supported by an educational grant from AstraZeneca.
Click on the "Start program" icon. If you are not already logged in to the site, this will bring you to the login/registration page where you will be able to register as a new cmecorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
Clicking "start the program" on the next screen will bring you to instructions to turn off pop-up blockers and allow you to begin the program presentation which will take approximately 60 minutes to complete.
The next screen will permit you to check for or download the Flash player required to run this program.
Upon completion of the program, click on the post-test button to access the post-test and program evaluation.
Instructions for completing and submitting the post-test are provided on the post-test screen. A minimum score of 70% on the post-test is required for a CME/CPE certificate.
None of the contents of this activity may be reproduced in any form without prior written permission of the publisher. The opinions expressed in this activity are those of the speakers and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, AKH Inc., or AstraZeneca. Any medications, or other diagnostic or treatment procedures discussed by the program speakers should not be utilized by clinicians without evaluation of their patients’ conditions and of possible contraindications or risks, and without a review of any applicable manufacturer’s product information and comparison with the recommendations of other authorities.